OliX Pharmaceuticals, Inc (KOSDAQ:226950)
South Korea flag South Korea · Delayed Price · Currency is KRW
94,800
+5,300 (5.92%)
Jul 31, 2026, 3:30 PM KST

OliX Pharmaceuticals Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
17,26314,6675,67717,0649,3203,674
Revenue Growth
193.31%158.35%-66.73%83.09%153.66%48.50%
Gross Profit
16,96314,3345,42816,9049,1133,503
Operating Income
-32,516-29,972-30,919-18,185-22,376-24,229
Net Income
-12,248-15,743-40,659-19,102-19,495-29,715
Earnings Per Share
-596.21-800.46-2414.00-1324.00-1422.69-2171.18
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
108,394132,51312,41425,92561,87249,757
Total Debt
21,79323,28739,19239,35743,99637,271
Net Cash (Debt)
86,601109,227-26,778-13,43317,87612,487
Net Cash Growth
----43.16%-76.70%
Net Cash Per Share
4215.715553.79-1589.86-930.931304.50912.36

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-20,940-15,900-28,045-21,168-30,683-19,054
Capital Expenditures
-1,037-1,262-13,465-8,826-2,233-1,290
Free Cash Flow
-21,977-17,161-41,510-29,995-32,916-20,344
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
98.26%97.73%95.62%99.06%97.78%95.33%
Operating Margin
-188.36%-204.36%-544.62%-106.57%-240.07%-659.40%
Pretax Margin
-56.52%-90.35%-723.44%-106.48%-312.30%-816.40%
Profit Margin
-70.95%-107.34%-716.18%-111.94%-209.17%-808.70%
FCF Margin
-127.31%-117.01%-731.17%-175.77%-353.16%-553.66%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
115.67193.2762.6313.6929.92152.91